Abstract
The PI3K pathway is often aberrantly activated in estrogen receptor positive (ER(+)) breast cancer and therapies combining PI3K inhibitors and antiestrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing and that alternate dosing schedules are equally active, further clinical exploration is warranted. Clin Cancer Res; 22(9); 2099-101. ©2016 AACRSee related article by Yang et al., p. 2250.
©2016 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Female
-
Humans
-
Molecular Targeted Therapy / methods
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptors, Estrogen / metabolism
-
Signal Transduction / drug effects
Substances
-
Antineoplastic Agents
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Receptors, Estrogen